Research programme: heterocyclic hydrazone therapeutics - Vion
Alternative Names: EPH 116; EPH 135; EPH 136; EPH 278; EPH 279; EPH 280; EPH 286; EPH 289; EPH 349; EPH 350; EPH 351; EPH 369; EPH 52Latest Information Update: 13 Jul 2009
At a glance
- Originator Austria Wirtschaftsservice; University of Innsbruck
- Developer Vion Pharmaceuticals
- Class Heterocyclic compounds; Hydrazones
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 13 Jul 2009 No development reported - Preclinical for Cancer in USA (unspecified route)
- 30 Apr 2007 Preclinical development is ongoing in USA
- 26 Apr 2006 Data presented at the 97th Annual Meeting of the American Association for Cancer Research (AACR-2006) have been added to the Cancer pharmacodynamics section ,